Aberrant Wnt activation is highly prevalent in most cancers of the digestive system including colorectal and liver cancers.547 So far, multiple efforts to target Wnt signaling in solid cancers have not met the expectations.548 Two classes of Wnt inhibitors have been most extensively investigated in clinical trials: porcupine inhibitors and DKK1 antagonists. This evidence concerns the gene DKK1 and cancer.